论文部分内容阅读
目的观察我院吸入噻托溴铵粉雾剂治疗慢性阻塞性肺疾病(COPD)的临床疗效。方法 86例COPD患者随机分为两组,治疗组(n=43)吸入噻托溴铵粉雾剂。对照组(n=43)吸入异丙托溴铵气雾剂。观察两组用药后10 d的临床症状、第一秒用力呼气容积(FEV1)占预计值的百分比(FEV1%预计值)及第一秒用力呼气容积占用力肺活量的百分比(FEV1/FVC)。结果治疗组的临床症状改善情况优于对照组(P<0.05),FEV1%预计值及FEV1/FVC与对照组相比显著提高(P<0.01)。结论吸入噻托溴铵治疗CDPD可明显改善症状,提高FEV1%预计值及FEV1/FVC,无严重药物不良反应。
Objective To observe the clinical effect of inhalation of tiotropium bromide in our hospital on chronic obstructive pulmonary disease (COPD). Methods Totally 86 COPD patients were randomly divided into two groups. The treatment group (n = 43) inhaled tiotropium bromide powder. The control group (n = 43) inhaled ipratropium bromide aerosol. The clinical symptoms, the first-second forced expiratory volume (FEV1) as a percentage of predicted value (FEV1% predicted), and the first-second forced expiratory volume-occupancy force (FEV1 / FVC) . Results The improvement of clinical symptoms in the treatment group was better than that in the control group (P <0.05). The predicted FEV1% and FEV1 / FVC were significantly higher than those in the control group (P <0.01). Conclusion The treatment of CDPD with tiotropium can improve the symptoms, improve the predictive value of FEV1% and FEV1 / FVC, without serious adverse drug reactions.